Estrogens in vascular biology and disease:: where do we stand today?

被引：59
|
作者：
Arnal, Jean-Francois
Scarabin, Pierre-Yves
Tremollieres, Florence
Laurell, Henrik
Gourdy, Pierre
机构：
[1] CHU Toulouse Rangueil, Dept Vasc Biol & Atherothrombosis, INSERM, U858,12MR, F-31432 Toulouse 4, France
[2] Hop Paul Brousse, Cardiovasc Epidemiol Team, Villejuif, France
来源：
CURRENT OPINION IN LIPIDOLOGY | 2007年 / 18卷 / 05期
关键词：
atheroma; atherosclerosis; cardiovascular risk; oestrogens; thrombosis;
D O I：
10.1097/MOL.0b013e3282ef3bca
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
A better understanding of the balance between the deleterious and beneficial effects of estrogens is required and should help to improve hormonal therapy safety and to optimize the prevention of cardiovascular disease after menopause.
引用
收藏
页码：554 / 560
页数：7
相关论文
共 50 条
  • [1] High density lipoprotein in atherosclerosis and coronary heart disease: Where do we stand today?
    Zvintzou, Evangelia
    Karampela, Dimitra Sotiria
    Vakka, Aggeliki
    Xepapadaki, Eva
    Karavia, Eleni A.
    Hatziri, Aikaterini
    Giannopoulou, Panagiota C.
    Kypreos, Kyriakos E.
    VASCULAR PHARMACOLOGY, 2021, 141
  • [2] 4 years after withdrawal of rofecoxib: where do we stand today?
    Jaksch, W.
    Dejaco, C.
    Schirmer, M.
    RHEUMATOLOGY INTERNATIONAL, 2008, 28 (12) : 1187 - 1195
  • [3] Coronary CT angiography and coronary atherosclerosis: Where do we stand today?
    Achenbach S.
    Herz, 2023, 48 (5) : 352 - 358
  • [4] 4 years after withdrawal of rofecoxib: where do we stand today?
    W. Jaksch
    C. Dejaco
    M. Schirmer
    Rheumatology International, 2008, 28
  • [5] Colchicine in Coronary Artery Disease: Where Do We Stand?
    Bonaventura, Aldo
    Potere, Nicola
    Liberale, Luca
    Kraler, Simon
    Weber, Brittany N.
    Abbate, Antonio
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2025, 85 (04) : 243 - 247
  • [6] Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?
    Tsioulos, Georgios
    Kounatidis, Dimitris
    Vallianou, Natalia G.
    Poulaki, Aikaterini
    Kotsi, Evangelia
    Christodoulatos, Gerasimos Socrates
    Tsilingiris, Dimitrios
    Karampela, Irene
    Skourtis, Alexandros
    Dalamaga, Maria
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (06)
  • [7] Drug-Eluting Stents in Animals and Patients Where Do We Stand Today?
    Drachman, Douglas E.
    CIRCULATION, 2009, 120 (02) : 101 - 103
  • [8] Omega 3: Where do we stand?
    Versari D.
    Daghini E.
    Salvetti G.
    Salvetti A.
    High Blood Pressure & Cardiovascular Prevention, 2008, 15 (4) : 225 - 230
  • [9] Antibiotic therapy in coronary heart disease -: Where do we currently stand?
    Anand, V
    Gupta, S
    CARDIOVASCULAR DRUGS AND THERAPY, 2001, 15 (03) : 209 - 210
  • [10] Antibiotic Therapy in Coronary Heart Disease—Where Do We Currently Stand?
    Vijay Anand
    Sandeep Gupta
    Cardiovascular Drugs and Therapy, 2001, 15 : 209 - 210
12345